Scholarlink

<p>Recent advancements in tuberculosis (TB) treatment are reshaping how the disease is understood and managed, particularly through improved differentiation between TB infection and active disease, which enables more tailored treatment approaches. Rifapentine-based regimens are at the forefront, offering shorter treatment durations and better patient adherence, making them especially valuable for individuals living with HIV or managing multiple comorbidities. While these advancements offer great potential, the letter stresses the ongoing challenges faced by marginalized populations, including delayed diagnosis and poor access to quality care, which hinder global TB control efforts. It calls for availability of rifapentine in Europe to ensure equitable treatment access and support the WHO’s TB eradication goals.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Is the unavailability of rifapentine holding back the end TB strategy in Europe? Implication for tuberculosis control among migrants and refugees

  • 期刊论文

  • 发表日期：

    2025年12月16日

查看全文
  • Salvatore Rotundo,
  • Francesca Serapide,
  • Giacomo Guido,
  • Francesco Di Gennaro,
  • Alessandro Russo

摘要

Recent advancements in tuberculosis (TB) treatment are reshaping how the disease is understood and managed, particularly through improved differentiation between TB infection and active disease, which enables more tailored treatment approaches. Rifapentine-based regimens are at the forefront, offering shorter treatment durations and better patient adherence, making them especially valuable for individuals living with HIV or managing multiple comorbidities. While these advancements offer great potential, the letter stresses the ongoing challenges faced by marginalized populations, including delayed diagnosis and poor access to quality care, which hinder global TB control efforts. It calls for availability of rifapentine in Europe to ensure equitable treatment access and support the WHO’s TB eradication goals.